Women sixty five and over with early stage breast cancer who do not have radiation after surgery may have an increased risk of a local recurrence or development of a new primary breast tumor.

Half of the women diagnosed with breast cancer are sixty five and over. Past studies have shown that older women are less likely to be offered chemotherapy, hormonal treatments or radiation. Young women are more likely to receive aggressive treatment for their breast cancer.

This study showed some important things:

1. Women in the study who had a lumpectomy without radiation were found to have an greater risk of a local recurrence.
2. Women in the study who received hormonal therapy and stayed on their treatment for the full five years had less of a recurrence rate than those who prematurely stopped the medication.

If you are over the age of sixty five and have been diagnosed with early-stage breast cancer, talk to your doctor about the risks and benefits of receiving radiation after surgery.

A new study sheds new hopeful light on pancreatic cancer survival -- for patients 65 and older.

The study, conducted at Thomas Jefferson University and Thomas Jefferson University Hospital in Philadelphia, found patients in this age group who survive pancreatic cancer for at least five years have a better chance than patients not yet 65 at surviving another five years.

Researchers studied the records of 890 patients with pancreatic cancer who underwent the standard pancreaticoduodenectomy, or Whipple procedure. And lead researcher Charles Yeo reports that surgery can in fact extend and improve the quality of life for this population.

"Not too long ago, few lived for five years after diagnosis," he said. "Today, that not true. There's been a paradigm shift in the way we treat and think about this disease."

Additional details on this promising study can be found in the journal Surgery.

Cancer survivors can have a lot of support when going through treatment. After all the surgeries, radiation and chemotherapy the survivors are usually stuck in a weird place. We are done treatment but sometimes at that point the fear can really kick in. During treatment and doctor visits we are busy fighting the cancer but after that period is over we are left with just the hope that we will not have a recurrence.

Animals can be very therapeutic. I didn't plan on buying a dog after my treatment ended. It just happened. My husband and I were shopping for clothes and wandered into the pet shop. We saw the cutest dog in the world. We took him home that day in October of 2002. I had just finished up my chemotherapy and radiation for breast cancer. I never had a dog before. I looked at him on my lap and thought "what did we just do?" Well, we did the best thing ever!

Steve will be four this month. It's been four years since my treatment ended and Steve has been with me to help me through the hard days. One look at his cute face and I feel better and worry less. I see how he lives for the moment and enjoys his life. He is such a good friend!

"The outside of a horse is good for the inside of a child" - Will Rogers

Researchers are suggesting not all men diagnosed with early stage prostate cancer need aggressive treatment, but may do just as well with a watchful waiting approach of periodic monitoring of the progression of their prostate cancer before medical action is taken.

When the records of 71,602 men diagnosed with localized or regional prostate cancer were evaluated, University of Michigan in Ann Arbor researchers concluded that over half of the men considered in the lower risk category who might have qualified for watchful waiting underwent immediate treatment instead.

The lower risk group would be men of any age at diagnosis with well-differentiated tumors or men 70 years or older at diagnosis with moderately differentiated tumors.

At the end of May, we told you about Abraham Starchild Cherrix, a teenager diagnosed with Hodgkin's lymphoma, who went through three months of chemotherapy only to have the cancer return months later. When his doctors recommended more chemotherapy and radiation, Cherrix, with the support of his parents, refused. Cherrix was concerned about the toxic effects of chemotherapy and radiation. He had chosen alternative therapies involving a bible-based diet and Hoxsey formula involving herbs and nutrition.

When Cherrix, who is now 16, said thanks but no thanks to the team of doctors recommending chemotherapy and radiation, a state social worker stepped in, filed with the court to gain joint custody of Cherrix and asked the court to require the teen to undergo standard cancer treatments of chemotherapy and radiation. Last Friday, the judge ruled in favor of the state and against the wishes of Cherrix. The court ordered Cherrix to report to the hospital for treatment.

To this Cherrix said he would defy the court order. He was not going to the hospital and he was not going to submit himself to conventional cancer treatments. Today, a second judge set aside the court order and returned legal custody of Cherrix to his parents. Cherrix is not, at this time, required to report the hospital. A trial date has been set for August 16 that seeks to require Cherrix to undergo chemotherapy and radiation.

Do you think the state has gone to far into the private life of a family, or do you think the parents are being negligent? Does a teenage boy of 16 have a right to decide his medical care?

I remember reading that Barbara Delinsky, novelist and breast cancer survivor, never shared her diagnosis of cancer until well after her fight was over. She feared the news would somehow halt her career in the publishing world. She wanted to remain untainted by disease in the eyes of her readers and bosses so she saved her secret. The secret is out now -- and is also part of a book she wrote called Uplift: Secrets from the Sisterhood of Breast Cancer Survivorship. She is in the clear now -- but she once feared the consequences of managing both cancer and her career.

The experts who offer a website resource at cancerandcareers.org believe that it is possible to combine cancer and career without fear or worry or secrecy. The advice provided on this site offers wisdom for working women and for employers and for co-workers. There is also a forum for shared stories -- where all of these individuals weigh in on their experiences. There are reading recommendations and a listing of available programs and services and a complete story about how this all came about.

Five years ago, the Board of Directors at Cosmetic Executive Women -- the preeminent nonprofit organization representing women in the U.S. and European beauty industries -- realized that five out of their 40 members had been diagnosed with cancer. Some told their colleagues at work and some did not. But all continued to work and experienced similar challenges. The fact is that work does not stop for all women who have been diagnosed with cancer. So the mission of this group is to help women, their employers, coworkers, and caregivers deal with this problem in the same way that they have learned to deal with problems at work -- strategically, knowledgeably, and effectively. With the right tools, stress and difficulty can be minimized. And this site is one great tool.

While the effectiveness of a seaweed extract acting as a potent inhibitor of human papilloma viruses, HPV, that can lead in some cases to cervical cancer, has not been tested in any human clinical trials -- in the lab it has impressed the National Cancer Institute researchers who have been studying it.

According to researchers, carrageenan extracted from marine red algae (seaweed) showed a thousand-fold greater potency compared with other inhibitors they have tested in halting HPV.

Dr. John Schiller, senior investigator at the National Cancer Institute, who was involved in the development of the HPV vaccine, made the carrageenan discovery.

Schiller cautions that the results do not prove that carrageenan will work as a practical HPV topical microbicide. However, the positive results in the lab, together with the fact that carrageenan-based over-the-counter products are already available -- make carrageenan look even more promising to researchers in blocking the sexual transmission of HPV.

The new cervical cancer vaccine is effective for about 70 percent of the HPV viruses that can cause cervical cancer. It is also an expensive vaccine that might prove cost prohibitive for low-income women in economically distressed countries. The researchers think, if carrageenan proves as effective in human clinical trails as it has in the lab, the inexpensive carrageenan could be a significant benefit in the prevention of HPV.

One researcher, Dr. Connie Trimble, an HPV researcher at Johns Hopkins University, feels so positive about the recent advancements and discoveries in relation to cervical cancer that she said, "With all the potential tools now, we could really start to think about the end of cervical cancer. Between the vaccines and some of the prophylactics -- wouldn't that be a medical success story!"

Fast food and junk food snacks are not good for health. Smoking is not good for health. Little sleep and non-existent periods of relaxation are not good for health. Lack of exercise and weight gain from stress eating are not good for health. But according to researchers, women who work long hours are prone to some or all these habits, and that is not a good thing for their health. Smoking, damage to the immune system due to unrelenting levels of stress, lack of exercise and weight gain all increase cancer risks.

Leeds University conducted a study that showed women typically respond to the stress of working long hours by engaging in negative habits that are detrimental to their immediate and long-term health. According to researchers, the reaction to stress can manifest in choosing unhealthy high fat and high sugar snacks before choosing healthier food.

The study compared how men and women respond to stress, and if there was a difference. Some experts stated that men are less likely to be affected by working long hours because they are not expected to multi-task when they get home from work in the same way women are expected to do. Researchers said most women agree to their take on the matter.

Knowing that some women alleviate stress in unhealthy ways, gives women an opportunity to step back and assess how they might choose better strategies for dealing with stress -- or in minimizing some of the causes of stress in their life. Aside from these research findings, I think both men and women in modern society are under enormous daily stress and we all need to step back and evaluate how much of our health we are willing to compromise.

Michael Fumento is an author, journalist, and attorney specializing in science and health issues. And he has a lot to say about the Surgeon General's recent announcement that the second-hand smoke debate is over -- that second-hand smoke does in fact kill. Fumento believes that the debate is over means if you have your doubts, then keep them to yourself -- that the topic is not up for discussion any longer. But Fumento states that we should definitely have doubts -- about the effects of second-hand smoke and about what the Surgeon General has to say about it.

In most cases, by the time someone notices the signs and symptoms of cancer, the cancer has developed past the early stage when it is most treatable. That is why there is so much emphasis on annual cancer screening for the most common cancers. That is the traditional wisdom.

As a result of the Mayo Lung Project study, researchers are saying the opposite. Basically, they are warning us not to go looking for trouble. It seems high-tech imaging technology can detect very small lung abnormalities that might be clinically unimportant but lead to over diagnosis of lung cancer, and subsequent toxicity and premature death from treatments for lung cancer.

The researchers placed patients in two groups. One group received multiple screening chest x-rays and spectrum tests used to identify lung cancer. The other group did not have any screening. 585 cancers were diagnosed in the first group, while 500 cancers were diagnosed in the second group.

The researchers concluded there is a very real and harmful role that over diagnosis plays in mass screening and the question remains if early detection of lung cancer through mass screening results in a net benefit to the public's health. Knowing this, I would still want to be screened. I might opt in getting second and third opinions in exploring treatment options before I rushed into any treatment though.

Someone once told me to think of cancer as a chronic condition -- an illness like diabetes or asthma that may linger for life and may require continual treatment. And while battling cancer, perhaps for life, I should just hope that medical advances occur and new treatments become available. And maybe, just maybe, the science of medicine will decrease by leaps and bounds the number of people who die from cancer.

During my own battle with cancer -- which has been 18 months long -- two new breast cancer drugs have hit the scene with rave reviews from researchers and medical professionals. This is good news for me because my type of breast cancer makes me a candidate for both drugs. Herceptin is one of these drugs -- given to women who are HER-2/neu positive -- that's me -- and over express a protein that makes the tumor aggressive. Herceptin is received over 52 weeks -- and I go every three weeks for a 90-minute infusion of this clear liquid that causes me really no side effects at all. It can be toxic to the heart but monitoring tests have revealed that my heart is not suffering at this time. And with just three more infusions to go -- one this Wednesday -- I will likely encounter no adverse reactions to this potentially life-saving drug.

And now Tykerb is making headlines. Tykerb, suggested for use with advanced breast cancer and manufactured by British-based GlaxoSmithKline PLC, is an experimental drug that delays the growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin. This finding, reported this past Saturday at a meeting in Atlanta of the American Society of Clinical Oncology, confirms initial findings about the promise of this drug -- that like Herceptin, made by Genentech, precisely targets tumors without killing lots of healthy cells. The difference between the two drugs is that Herceptin blocks the protein on the cell's surface and Tykerb does it inside the cell -- blocking a second abnormal protein too. And while Herceptin is given intravenously, Tykerb is given in pill form -- which may make it cheaper and easier to use.

While now part of an international study, Tykerb may be available to women in the United States later this year. And it perhaps will be offered in conjunction with Herceptin or instead of Herceptin for women with advanced breast cancer.

I hope I do not ever need Tykerb -- and that Herceptin alone will be enough for me -- but it is comforting to know that there is something else out there. Something that if necessary, just might help me live with this potentially chronic condition called cancer.